Bladder Cancer Clinical Trial

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Summary

The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.

View Full Description

Full Description

In this prospective, observational study, investigators are assessing the optimal approach to treating bladder cancer in older participants with other disease that might put the participants at additional risk from cancer-directed treatments. Investigators are specifically assessing the impact on adverse events, quality of life, and treatment outcomes. Additionally, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants.

The research study procedures include screening for eligibility and completing questionnaires.

Participation in this research study is expected to last for up to 8 months.

It is expected that about 180 people will take part in this research study.

The National Comprehensive Cancer Network and EMD Serono are supporting this research study by providing the necessary funds.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥65-years-old (study will limit total enrollment of patients between ages 65-70 to 20% of the total study population)
Unresectable or metastatic bladder cancer with histologically proven urothelial carcinoma. Any component of variant histology is allowed
Cisplatin-ineligible as determined by the subject's primary oncologist
Receiving treatment with chemotherapy (+/- immunotherapy maintenance), enfortumab vedotin-pembrolizumab combination therapy or immunotherapy alone
Ability to understand and the willingness to sign a written informed consent document and to complete patient reported outcomes that will be in English or Spanish either alone or with assistance of study researcher or family

Exclusion Criteria:

Subjects who elect to not undergo cancer-directed therapy
Subjects obtaining their care outside of DFCI or DFCI affiliate sites
Advanced cognitive impairment or inability to complete surveys
Participants who are receiving any other investigational agents for this condition (if appropriate only).

Study is for people with:

Bladder Cancer

Estimated Enrollment:

180

Study ID:

NCT06138561

Recruitment Status:

Recruiting

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Joaquim Bellmunt, MD, PhD
Contact
617-632-2010
[email protected]
Joaquim Bellmunt, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

180

Study ID:

NCT06138561

Recruitment Status:

Recruiting

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.